Stockscreener 앱 받기
0.5109
10.35%
-0.059
시간 외 거래:
.53
0.0191
+3.74%
전일 마감가:
$0.5699
열려 있는:
$0.565
하루 거래량:
56,098
Relative Volume:
0.82
시가총액:
$8.52M
수익:
$2.82M
순이익/손실:
$-14.20M
주가수익비율:
-0.6011
EPS:
-0.85
순현금흐름:
$-15.13M
1주 성능:
-12.82%
1개월 성능:
-5.20%
6개월 성능:
-34.50%
1년 성능:
-53.55%
1일 변동 폭
$0.49
$0.565
1주일 범위
$0.45
$0.6498
52주 변동 폭
$0.45
$1.27
Talphera Inc Stock (TLPH) Company Profile
명칭
Talphera Inc
전화
650-216-3500
주소
1850 GATEWAY DRIVE, SAN MATEO
TLPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLPH
Talphera Inc
|
0.5109 | 8.52M | 2.82M | -14.20M | -15.13M | -0.85 |
|
ZTS
Zoetis Inc
|
151.73 | 69.57B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.72 | 47.40B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.89 | 46.06B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.80 | 15.98B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
292.46 | 13.58B | 2.76B | 1.11B | 898.10M | 22.77 |
Talphera Inc Stock (TLPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2020-07-20 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2019-11-11 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-05 | 재개 | Credit Suisse | Outperform |
| 2019-07-10 | 재개 | Credit Suisse | Outperform |
| 2019-04-24 | 재개 | B. Riley FBR | Buy |
| 2019-02-15 | 개시 | Credit Suisse | Outperform |
| 2018-10-23 | 개시 | B. Riley FBR | Buy |
| 2017-10-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2017-10-13 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-07-14 | 재개 | Jefferies | Buy |
| 2016-09-15 | 재확인 | ROTH Capital | Buy |
| 2016-08-05 | 다운그레이드 | Stifel | Buy → Hold |
| 2015-10-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2015-10-05 | 재확인 | ROTH Capital | Buy |
| 2015-09-02 | 개시 | H.C. Wainwright | Buy |
| 2015-07-10 | 재개 | ROTH Capital | Buy |
| 2015-05-06 | 재확인 | Mizuho | Neutral |
| 2015-05-05 | 재확인 | RBC Capital Mkts | Outperform |
| 2015-03-10 | 재확인 | RBC Capital Mkts | Outperform |
| 2015-03-09 | 다운그레이드 | Mizuho | Buy → Neutral |
모두보기
Talphera Inc 주식(TLPH)의 최신 뉴스
HC Wainwright Estimates Talphera FY2029 Earnings - Defense World
Talphera CEO Makes Bold Move with Major Stock Purchase! - TipRanks
Talphera CEO Vincent Angotti buys $124,999 in common stock By Investing.com - Investing.com Canada
Talphera CEO Vincent Angotti buys $124,999 in common stock - Investing.com
Talphera (NASDAQ:TLPH) Given Buy Rating at HC Wainwright - Defense World
Talphera, Inc. Earnings Call: Progress Amid Challenges - TipRanks
H.C. Wainwright maintains Buy on Talphera stock, $6 target By Investing.com - Investing.com Canada
H.C. Wainwright maintains Buy on Talphera stock, $6 target - Investing.com India
Talphera: Q4 Earnings Snapshot - CT Insider
Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights - Yahoo Finance
Talphera Reports 2024 Financial Results and Study Update - TipRanks
Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad - MSN
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus - Investing.com India
FDA approves Talphera’s reduced NEPHRO CRRT study size By Investing.com - Investing.com South Africa
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus By Investing.com - Investing.com UK
TLPH stock touches 52-week low at $0.5 amid market challenges By Investing.com - Investing.com South Africa
TALPHERA, INC. SEC 10-K Report - TradingView
Talphera Inc reports results for the quarter ended December 31Earnings Summary - TradingView
FDA approves Talphera’s reduced NEPHRO CRRT study size - Investing.com India
Talphera reports Q4 EPS (7c) vs. (25c) last year - TipRanks
FDA Green Light: Talphera Slashes Trial Size by 58% as Q4 Losses Drop 57% - Stock Titan
TLPH stock touches 52-week low at $0.5 amid market challenges - Investing.com
Talphera to Reduce Size of Renal Replacement Therapy Study, Enters Private Placement; Shares Fall - MarketScreener
Talphera Scores Major FDA Win: NEPHRO Study Size Slashed by 58% While Securing $14.8M Backing - Stock Titan
Earnings Outlook For Talphera - Benzinga
Talphera to Unveil 2024 Performance: Key Financial Results and Strategic Updates Coming March 31 - Stock Titan
Talphera Inc expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Talphera (TLPH) Expected to Announce Earnings on Wednesday - Defense World
Talphera chief medical officer Aslam Shakil purchases $6,038 in stock By Investing.com - Investing.com South Africa
Talphera chief medical officer Aslam Shakil purchases $6,038 in stock - Investing.com
Talphera (NASDAQ:TLPH) Stock Price Down 1.9% – Here’s What Happened - Armenian Reporter
Talphera Inc (NASDAQ: TLPH) Is On The Rise - Stocks Register
RODMAN&RENSHAW Upgrades Talphera (NASDAQ:TLPH) to Strong-Buy - Defense World
Rodman & Renshaw sets Talphera stock Buy rating, $4 target - MSN
Talphera (NASDAQ:TLPH) Receives “Buy” Rating from HC Wainwright - Defense World
FDA to review Talphera's request to amend NEPHRO study By Investing.com - Investing.com Canada
FDA to review Talphera’s request to amend NEPHRO study By Investing.com - Investing.com Nigeria
FDA to review Talphera's request to amend NEPHRO study - Investing.com
Talphera Announces Agreement with the FDA for Prior Approval Supplement Review to Reduce the Number of Patients in the NEPHRO CRRT Study - The Eastern Progress Online
Talphera's NEPHRO CRRT Study Gains FDA Backing for Accelerated Patient Enrollment - Stock Titan
TLPH stock touches 52-week low at $0.6 amid market shifts - Investing.com UK
TLPH stock touches 52-week low at $0.61 amid market challenges - Investing.com
Talphera faces Nasdaq delisting over share price rule - Investing.com
Talphera faces Nasdaq delisting over share price rule By Investing.com - Investing.com UK
Acelrx Announces Dsuvia® Milestone C Approval; Provides Revenue Guidance for the First Quarter 2020 - Marketscreener.com
Talphera to Host Third Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, November 13, 2024 - Kilgore News Herald
Talphera CEO Vincent J. Angotti acquires $3,199 in common stock - Investing.com
Talphera CEO Vincent J. Angotti acquires $3,199 in common stock By Investing.com - Investing.com UK
Talphera CEO Vincent J. Angotti buys $3,649 in company stock By Investing.com - Investing.com Canada
Talphera CFO Raffi Asadorian sells shares worth $118 - Investing.com India
Talphera CEO Vincent J. Angotti buys $3,649 in company stock - Investing.com India
Talphera Inc (TLPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Talphera Inc 주식 (TLPH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Aslam Shakil | Chief Medical Officer |
Jun 14 '24 |
Buy |
1.07 |
5,000 |
5,357 |
37,695 |
| Aslam Shakil | Chief Medical Officer |
Jun 13 '24 |
Buy |
0.98 |
695 |
681 |
32,695 |
| Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Dec 05 '24 |
Buy |
0.64 |
5,000 |
3,200 |
208,066 |
| ASADORIAN RAFFI | Chief Financial Officer |
Dec 02 '24 |
Sale |
0.77 |
155 |
119 |
37,578 |
| Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Nov 27 '24 |
Buy |
0.73 |
5,000 |
3,650 |
203,066 |
5.86%
자본화:
|
볼륨(24시간):